BALA CYNWYD, Pa., Sept. 6, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Astex Pharmaceuticals, Inc. ("Astex" or the "Company") (Nasdaq: ASTX ) relating to the proposed acquisition by Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). Click here to learn more about the investigation http://brodsky-smith.com/635-astx-astex-pharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or obligation to you. Under the terms of the transaction, Astex shareholders will receive only $8.50 in cash for each share of Astex stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Astex for not acting in the Company's shareholders' best interests in connection with the sale process. The transaction may undervalue the Company as analysts have set price targets of $13.00 per share and $9.00 per share.